Last year, Pfizer ($PFE) got a federal judge to toss an investor lawsuit tied to its now-withdrawn pain drug Bextra. But that wasn't the only investor suit raising similar issues--namely that Pfizer's board had not been forthright about marketing allegations involving Bextra and other drugs. When they were made public, those allegations sank Pfizer's shares. Another of those shareholder suits was just days away from trial last quarter when the drugmaker agreed to settle it for $400 million. Report